Neuromyelitis Optica Spectrum Disorder
41
12
16
13
Key Insights
Highlights
Success Rate
81% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.3%
3 terminated out of 41 trials
81.3%
-5.3% vs benchmark
24%
10 trials in Phase 3/4
69%
9 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (41)
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Ofatumumab in AQP4-IgG Seropositive NMOSD
Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
French Registry for Monitoring Pregnancies for Multiple Sclerosis
Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder
Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
Biomarkers in Autoimmune Disease of Nervous System